Clinical TrialMay 7, 2026, 09:32 AM
Aardvark Therapeutics Pauses ARD-101/201 Programs; Q1 Net Loss $21.6M
AI Summary
Aardvark Therapeutics announced a voluntary pause in enrollment and dosing for its ARD-101 and ARD-201 clinical programs. This decision followed unexpected reversible cardiac observations in a separate healthy volunteer trial, with further guidance expected in Q2 2026. For the first quarter ended March 31, 2026, the company reported a net loss of $21.6 million, an increase from $9.3 million in Q1 2025. Aardvark held $91.2 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into mid-2027.
Key Highlights
- Voluntary pause in ARD-101 and ARD-201 programs due to reversible cardiac observations.
- Net loss for Q1 2026 was $21.6 million, compared to $9.3 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $91.2 million as of March 31, 2026.
- Company projects existing cash to fund operations into mid-2027.
- R&D expenses increased to $16.6 million in Q1 2026 from $7.8 million in Q1 2025.
- G&A expenses rose to $5.9 million in Q1 2026 from $2.7 million in Q1 2025.
- Net loss per share was $(0.99) for Q1 2026, compared to $(0.71) for Q1 2025.